




RealRate

PHARMACEUTICAL 2021

Theravance Biopharma Inc
Rank 188 of 394

Theravance
Biopharma 
Medicines That Make a Difference®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Theravance Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Theravance Biopharma Inc is the variable Research and Development, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 275%, being 19% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	393,341
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	123,571
Liabilities, Non-Current	0
Other Assets	59,294
Other Compr. Net Income	-98
Other Expenses	36,065
Other Liabilities	0
Other Net Income	55,805
Other Revenues	71,857
Property and Equipment	16,422
Research and Development	260,953
Selling, General and Administrative Expense	108,661

Output Variable	Value in 1000 USD
Assets	469,057
Liabilities	123,571
Expenses	405,679
Revenues	71,857
Stockholders Equity	345,486
Net Income	-278,017
Comprehensive Net Income	-278,066
BaseVar	563,034
ECR before LimitedLiability	160%
Economic Capital Ratio	275%